LEO Pharma Ranks Second in Global Clinical Trials Transparency Audit

Food and Healthcare Press Releases Monday July 31, 2017 08:15
BALLERUP, Denmark and HURLEY, England--31 Jul--PRNewswire/InfoQuest
New top 50 list ranks LEO Pharma in second position, leading the global pharma industry in commitments to increase access to clinical trials information
(Logo: http://photos.prnewswire.com/prnh/20130221/595427 )
The AllTrials audit on clinical trial transparency findings has been published ranking LEO Pharma as leaders in the industry.

LEO Pharma is ranked at number two out of the 50 pharmaceutical companies evaluated. AllTrials is an international campaign that calls for every clinical trial, past and present, to be registered and their results reported. The rankings assess companies' policy commitments on disclosing trial registrations, summary findings of studies, comprehensive clinical study reports (CSRs) and individual patient data (IPD).

As one of the companies in the forefront of data transparency LEO Pharma was early off the mark to globally commit to increased disclosure. Since making this commitment in 2013, LEO Pharma has made its clinical trials results dating back to 1990 available to the public and will share individual patient-level data upon request from qualified third-party researchers. The company's commitment to transparency and patient focus has also evolved with the completion of an innovative project to develop lay summaries for patients and interested parties in easy to understand language.

Commenting on the publication from AllTrials, Katherine Murphy, former CEO of The Patients Association (now Independent Care Consultant) said:

"I very much welcome these audit findings and greater transparency in clinical trials, as well as research and development generally. It is really pleasing to see more information on clinical trials becoming increasingly available in the public domain with companies like LEO Pharma amongst the leaders. The more information that patients and members of the public have will support them to become better placed to make informed decisions and treatment choices."

Kim Kjoeller, Executive Vice President Global Research and Development, LEO Pharma, said:

"The AllTrials rankings are a robust overview which, while grounded in empirical data, casts new light on the attitudes and approaches to transparency across our industry. LEO Pharma welcomes the AllTrials audit and we are delighted to see this positive recognition for our commitment to making our scientific evidence base freely available for scrutiny and study. Having just entered the biologics arena LEO Pharma is at a turning point in our company's history, and we are excited by the promise that our pipeline holds. Maintaining this commitment to openly sharing our vision through timely disclosure of trial information has never been more important to us, and we look forward to continuing to partner with the scientific community to drive the clinical trial transparency agenda to the next level."

For more information on LEO Pharma's commitment to transparency, please see the company's Position on Public Access to Clinical Trials Information at http://www.leo-pharma.com .
About LEO Pharma
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, the company supports people in managing their skin conditions.
Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to delivering products and solutions to people suffering from skin diseases.
LEO Pharma is globally headquartered in Denmark and employs around 4,800 people worldwide.
Contact:
Global Media Enquiries
Henrik Kyndlev
Corporate Communications Manager
+45-3140-6180
Henrik.kyndlev@leo-pharma.com
UK and Ireland Media Enquiries
Charlotte Murrain
Communications Manager
+44(0)7557-436-771
charlotte.murrain@leo-pharma.com
Julie Wong
Head of Communications
+44(0)7825-918-989
julie.wong@leo-pharma.com
Source: LEO Pharma A/S

Latest Press Release

The Consumer Health of Merck Walks the Talk with its WE100 Movement

- Consumer Health accelerates its WE100(R) movement by launching new partnership programme with pharmacists in the UK on enabling 100 years of healthy living - Femibion(R) celebrates working mums with new "MumPlus" campaign - Expansion of Vitamin D brand...

Mindray launches BeneVision N1 for uninterrupted monitoring during intra and out-of-hospital patient transport

The revolutionary transport solution extends intelligent monitoring to out-of-hospital transport settings such as ambulances, helicopters, and civic flights. Mindray, a global medical equipment solution provider, announced the release of BeneVision N1...

Photo Release: Fujitsu works with the Thai Red Cross Society to contribute to society through the annual 20th FTH Voluntary Blood Donation Day

Ms. Krittinee Sivakul, Head of HR & Administration Group, Fujitsu (Thailand) Co., Ltd. (FTH) led a group comprising company management and staff at a special executives and 187 employees of the company recently donated blood to the Thai Red Cross...

Systech Europe(TM) Announces Rapid Expansion of Customer Base and Pharmaceutical Serialisation Partners Ready to Meet the FMD Regulation

Systech International , the global technology leader in serialisation, track and trace, and brand protection grew its European presence in 2017 by 50% with new accounts in France, Germany, Greece, Turkey, and Finland. The company also added new...

Fluke Biomedical VT650 and VT900 Gas Flow Analyzers offer the highest accuracy on the market

New analyzers deliver ease-of-use and reliability in measurements for all types of ventilators, flow meters, pressure gauges, anesthesia machines, and other devices Fluke Biomedical introduces the VT650 and VT900 Gas Flow Analyzers , which include...

Related Topics